Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy or radiation therapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with topotecan, cyclophosphamide, cisplatin, and vincristine plus radiation therapy and peripheral stem cell transplant... Read More
Gender:
ALL
Ages:
Between 3 years and 20 years
Trial Updated:
11/06/2012
Locations: Texas Children's Cancer Center, Houston, Texas
Conditions: Brain and Central Nervous System Tumors
CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
Completed
Primary Objectives: * To determine the feasibility, activity, and toxicity of a novel regimen using a concurrent irinotecan (CPT-11)/cisplatin and celecoxib combination for patients with unresectable NSCLC. * To determine the maximal tolerance dose of celecoxib in patients with unresectable NSCLC treated with irinotecan/cisplatin and concurrent thoracic radiation therapy. * To correlate the COX-2 expression and other biomarkers with response to the treatment in the tumor from a pretreatment bio... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/19/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
Completed
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, doxorubicin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them before surgery, may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant combination chemotherapy works in treating patients undergoing radical cystectomy for locally advanced carcinoma of the urothelium.
Gender:
ALL
Ages:
All
Trial Updated:
10/18/2012
Locations: M.D. Anderson Cancer Center at University of Texas, Houston, Texas
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Completed
Primary Objective: 1. Assess the clinical activity defined by response rate of irinotecan and cisplatin in untreated patients with metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract. Secondary Objective: 1. To assess the safety profile of irinotecan and cisplatin in untreated patients with metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract.
Gender:
ALL
Ages:
All
Trial Updated:
08/01/2012
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Gastrointestinal Cancer, Carcinoma, Neuroendocrine
Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
Completed
The goal of this clinical research study is find the highest safe dose of cisplatin that can be given with liposomal doxorubicin in the treatment of advanced cancer involving the liver. PRIMARY Objectives: To determine the toxicity and safety of a monthly cytotoxic regimen combining intraarterial hepatic (HAI) cisplatin with systemic intravenous liposomal doxorubicin in patients with cancer metastatic to the liver. SECONDARY Objectives: To document in a descriptive fashion the antitumor effi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/01/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/27/2012
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Completed
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
Gender:
MALE
Ages:
14 years and above
Trial Updated:
07/27/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Penile Cancer
Taxotere/Temodar/Cisplatin Study in Melanoma Patients
Completed
Primary Objective: 1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma. Secondary Objectives: 1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma 2. To determine the response rate of induction chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Melanoma
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +7 locations
Conditions: Lung Cancer
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin is more effective when combined with paclitaxel or gemcitabine in treating cervical cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with paclitaxel to that of cisplatin combined with gemcitabine in treating women who have recurrent, persi... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/11/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +9 locations
Conditions: Cervical Cancer
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
Completed
Primary: 1. To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis (OM) in patients with sarcoma receiving multicycle chemotherapy. 2. To evaluate the pharmacokinetics (PK) of palifermin when given pre chemotherapy. 3. To evaluate the safety profile of palifermin when combined with multicycle chemotherapy. Exploratory: 1. To evaluate the biologic effect of palifermin on oral mucosa. 2. To investigate potential biomarker development by bioch... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
04/17/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Sarcoma, Oral Mucositis
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Completed
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2012
Locations: Pfizer Investigational Site, Houston, Texas
Conditions: Neoplasms